We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US FDA gave the drug an accelerated approval to treat relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic leukemia along with relapsed Chronic Lymphocytic Leukemia (CLL).